FY2026 Earnings Estimate for argenex Issued By HC Wainwright

argenex SE (NASDAQ:ARGX) – Analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of argenex in a research note issued on Friday, July 24th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $26.27 for the year, up from their previous forecast of $24.35. HC Wainwright currently has a “Buy” rating and a $940.00 target price on the stock. The consensus estimate for argenex’s current full-year earnings is $26.95 per share. HC Wainwright also issued estimates for argenex’s Q4 2026 earnings at $6.93 EPS, FY2027 earnings at $34.38 EPS, FY2028 earnings at $43.50 EPS, FY2029 earnings at $53.47 EPS and FY2030 earnings at $64.39 EPS.

Several other research firms have also commented on ARGX. Royal Bank Of Canada boosted their price objective on shares of argenex from $945.00 to $1,025.00 and gave the company an “outperform” rating in a research report on Friday. Oppenheimer raised their target price on shares of argenex from $1,014.00 to $1,037.00 and gave the stock an “outperform” rating in a report on Friday. Wells Fargo & Company lifted their price target on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research note on Monday, June 1st. Bank of America upped their price target on shares of argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. Finally, Wall Street Zen raised shares of argenex from a “hold” rating to a “buy” rating in a research report on Saturday. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,054.11.

argenex Stock Performance

NASDAQ:ARGX opened at $888.82 on Tuesday. The firm has a market capitalization of $55.60 billion, a PE ratio of 34.13, a PEG ratio of 1.21 and a beta of 0.45. The stock’s fifty day moving average is $870.53 and its 200 day moving average is $815.82. argenex has a fifty-two week low of $590.78 and a fifty-two week high of $953.58.

argenex (NASDAQ:ARGX) last announced its earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, topping analysts’ consensus estimates of $5.86 by $1.46. The firm had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ARGX. Merit Financial Group LLC lifted its holdings in argenex by 17.1% during the 2nd quarter. Merit Financial Group LLC now owns 466 shares of the company’s stock valued at $432,000 after buying an additional 68 shares in the last quarter. Farther Finance Advisors LLC grew its stake in argenex by 9.6% in the 2nd quarter. Farther Finance Advisors LLC now owns 365 shares of the company’s stock worth $338,000 after acquiring an additional 32 shares in the last quarter. Ballentine Partners LLC grew its stake in argenex by 30.8% in the 2nd quarter. Ballentine Partners LLC now owns 772 shares of the company’s stock worth $716,000 after acquiring an additional 182 shares in the last quarter. Peregrine Capital Management LLC purchased a new position in shares of argenex during the second quarter worth approximately $27,584,000. Finally, Sequoia Financial Advisors LLC increased its position in shares of argenex by 4.3% during the second quarter. Sequoia Financial Advisors LLC now owns 2,045 shares of the company’s stock worth $1,897,000 after acquiring an additional 84 shares during the period. 60.32% of the stock is currently owned by institutional investors.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx agreed to acquire Forte Biosciences (NASDAQ: FBRX) for $77 per share in cash, representing an equity value of approximately $2.2 billion and a 41% premium to Forte’s prior closing price. The transaction gives argenx full ownership of FB102, an experimental autoimmune therapy. argenx acquisition announcement
• Positive Sentiment: FB102’s Phase 1b data in vitiligo and celiac disease reportedly support CD122 biology and a potential “pipeline-in-a-product” opportunity targeting pathogenic T-cell and NK-cell activity in diseases with significant unmet need. The acquisition broadens argenx’s immunology pipeline beyond its existing portfolio. argenx Forte acquisition details
• Positive Sentiment: Analyst sentiment remains supportive in parts of the market: Robert W. Baird raised its price target to $932, while HC Wainwright increased its earnings estimates. A separate Oppenheimer report had previously lifted its target to $1,037.
• Neutral Sentiment: Baird maintained a “neutral” rating despite the higher target, implying that the acquisition’s long-term value is not yet fully reflected in near-term expectations. Baird price target report
• Negative Sentiment: The all-cash $2.2 billion transaction represents a substantial capital commitment for a clinical-stage asset. Investors may be concerned about integration costs, future development spending and the risk that FB102’s early-stage results do not translate into successful late-stage trials or commercialization. One analysis consequently rated the stock “Hold.” Forte and argenx investment analysis

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.